Herantis completes patient visits in Parkinson’s phase 1b trial

Published 14/08/2025, 14:14
Herantis completes patient visits in Parkinson’s phase 1b trial

ESPOO, Finland - Herantis Pharma Plc, a clinical-stage biotech company with a market capitalization of $55 million, announced Thursday that it has completed the final patient visit in its Phase 1b clinical trial evaluating HER-096 in Parkinson’s disease patients. According to InvestingPro data, the company’s stock has shown strong momentum, gaining over 30% in the past six months.

The trial’s final cohort consisted of patients receiving 300 mg doses of HER-096 or placebo administered subcutaneously twice weekly over a four-week period. The primary objective is to assess safety, tolerability and pharmacokinetics of repeated doses, while also evaluating selected biomarkers and monitoring symptoms.

Topline results from the Phase 1b trial are expected within six to nine weeks, with the full dataset including biomarker data anticipated before year-end, according to the company’s press release statement.

"We are pleased to have completed all patient dosing and follow-up visits in our Phase 1b study of HER-096," said Antti Vuolanto, CEO of Herantis Pharma.

The Phase 1b study consists of two parts. Part 1 involved eight healthy volunteers receiving a single 300 mg dose. Part 2 is a randomized, double-blind, placebo-controlled trial with Parkinson’s patients in two cohorts - the first receiving 200 mg doses and the second receiving 300 mg doses.

HER-096 is a small peptide molecule designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF), targeting key drivers of neurodegeneration in Parkinson’s disease. The company is developing it as a potential first disease-modifying treatment for the condition, which affects over 10 million people worldwide.

The trial is being conducted in Finland and is funded by The Michael J. Fox Foundation for Parkinson’s Research and Parkinson’s UK.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.